168,893 Shares in MiMedx Group, Inc $MDXG Purchased by Ieq Capital LLC

Ieq Capital LLC purchased a new stake in MiMedx Group, Inc (NASDAQ:MDXG) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 168,893 shares of the company’s stock, valued at approximately $650,000.

Other hedge funds have also added to or reduced their stakes in the company. SkyView Investment Advisors LLC increased its holdings in MiMedx Group by 3.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after purchasing an additional 3,032 shares in the last quarter. Rafferty Asset Management LLC lifted its holdings in shares of MiMedx Group by 4.6% in the fourth quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock valued at $469,000 after purchasing an additional 3,064 shares in the last quarter. Aviva PLC boosted its position in shares of MiMedx Group by 4.7% during the fourth quarter. Aviva PLC now owns 71,234 shares of the company’s stock valued at $482,000 after buying an additional 3,211 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of MiMedx Group by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock valued at $559,000 after buying an additional 4,049 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in MiMedx Group by 42.6% during the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after buying an additional 4,296 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Wall Street Zen raised shares of MiMedx Group from a “sell” rating to a “hold” rating in a report on Saturday. Cantor Fitzgerald reissued an “overweight” rating and set a $8.00 price target on shares of MiMedx Group in a research report on Monday, August 17th. Craig Hallum raised their price target on shares of MiMedx Group from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings restated a “sell (d)” rating on shares of MiMedx Group in a report on Thursday, August 13th. Finally, Raymond James Financial set a $8.00 price objective on shares of MiMedx Group in a research report on Monday, August 17th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.57.

MiMedx Group Price Performance

MiMedx Group stock opened at $4.50 on Friday. MiMedx Group, Inc has a 12 month low of $3.03 and a 12 month high of $7.97. The company has a current ratio of 5.33, a quick ratio of 4.79 and a debt-to-equity ratio of 0.07. The business’s 50 day simple moving average is $4.18 and its 200 day simple moving average is $4.09. The company has a market cap of $655.92 million, a price-to-earnings ratio of 112.53 and a beta of 1.45.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The business had revenue of $64.36 million during the quarter, compared to the consensus estimate of $63.46 million. MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%. Sell-side analysts forecast that MiMedx Group, Inc will post -0.1 EPS for the current year.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.